心源性休克体外生命支持成功撤机后的结局
本中心2015年1月至2020年12月共510例因心源性休克接受静脉-动脉体外生命支持的患者,其中249例(48.8%)成功撤机,撤机者中218例(87.6%)存活出院;急性心肌梗死病因、既往慢性肾病和启动连续肾脏替代治疗与撤机后院内死亡显著相关,出院者1年生存率为95.0%。
要点
- 510例中249例(48.8%)成功撤机,撤机者218例(87.6%)存活出院。
- 急性心肌梗死病因、既往慢性肾病、启动连续肾脏替代治疗与撤机后院内死亡显著相关。
- 成功撤机者出院后1年生存率95.0%,与桥接心脏移植或心室辅助装置者相当。
核心结论
- 因心源性休克接受体外生命支持的患者中相当比例可成功撤机,但成功撤机并不保证存活出院;出院者1年生存率仍高,与桥接心脏移植或心室辅助装置者相当。
研究设计与样本
- 单中心研究,纳入本中心2015年1月至2020年12月因心源性休克接受静脉-动脉体外生命支持的510例患者,其中249例成功撤机(撤机后存活30天或至出院)。
主要发现
- 510例中249例(48.8%)成功撤机,227例(44.5%)在体外生命支持期间或之后死亡,34例(6.7%)桥接至心脏移植或心室辅助装置。
- 原发性移植物功能障碍病因者成功撤机机会更高(OR 3.088;95%CI 1.1-8.671;P=.0323),心肺复苏期间接受体外生命支持者成功撤机机会降低(OR 0.354;95%CI 0.17-0.735;P=.0054)。
- 成功撤机的249例中218例(87.6%)存活出院,31例(12.4%)院内死亡。
- 急性心肌梗死病因(OR 4.751;95%CI 1.623-13.902;P=.0044)、既往慢性肾病(OR 3.422;95%CI 1.374-8.52;P=.0082)、启动连续肾脏替代治疗(OR 3.188;95%CI 1.291-7.871;P=.012)与成功撤机后院内死亡显著相关。
- 成功撤机且存活出院者1年生存率为95.0%,与接受心脏移植或心室辅助装置者的1年生存率相当。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Although extracorporeal life support (ECLS) has increasingly been used for the treatment of patients with cardiogenic shock (CS), the outcomes of those successfully weaned from support remain poorly defined. METHODS: Of 510 venoarterial ECLS CS patients at our institution between January 2015 and December 2020, 249 were decannulated and survived for 30 days or until discharge (ie, successfully weaned). Factors associated with survival to discharge were assessed and 1-year survival was described. RESULTS: Of 510 eligible CS ECLS patients, 249 (48.8%) were successfully decannulated, 227 (44.5%) died during/following ECLS, and 34 (6.7%) were bridged to heart transplantation or a ventricular assist device. Patients with a primary graft dysfunction etiology of CS had a greater chance of successful decannulation (odds ratio [OR], 3.088; 95% CI, 1.1-8.671; P = .0323), whereas patients with ECLS during cardiopulmonary resuscitation had a reduced chance of successful decannulation (OR, 0.354; 95% CI, 0.17-0.735; P = .0054). Of successfully decannulated patients, 218 (87.6%) survived to hospital discharge and 31 (12.4%) died in the hospital. Acute myocardial infarction etiology (OR, 4.751; 95% CI, 1.623-13.902; P = .0044), preexisting chronic kidney disease (OR, 3.422; 95% CI, 1.374-8.52; P = .0082), and initiation of continuous renal replacement therapies (OR, 3.188; 95% CI, 1.291-7.871; P = .012) were significantly associated with in-hospital mortality despite successful decannulation. One-year survival in successfully decannulated patients surviving to hospital discharge was 95.0% and comparable to 1-year survival in patients who received a heart transplant or ventricular assist device. CONCLUSIONS: Successful decannulation can be achieved in a significant proportion of patients treated with ECLS for CS but does not guarantee survival to hospital discharge. However, 1-year survival of hospital survivors remains high and is comparable to patients bridged to transplant or a ventricular assist device.
引用
- Zhang A, Kurlansky P, Ning Y, et al. Outcomes following successful decannulation from extracorporeal life support for cardiogenic shock. J Thorac Cardiovasc Surg. 2022. PMID: 36180251. doi:10.1016/j.jtcvs.2022.08.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。